Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0204


The up and down of KRAS testing for personalized colorectal cancer treatment

William CS CHO, MD, PhD.

Affiliation: William CS Cho, Scientific Officer, Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.

Tel: +852 2958 5441; +852 2958 5455


Since there is no abstract available we provide the first paragraph.
Recently, KRAS mutations testing has become popular in decision-making about the addition of EGFR inhibitors to chemotherapy in the treatment of patients with metastatic colorectal cancer (mCRC). A recent meta-analysis published in Clinical Colorectal cancer supports the clinical utility of KRAS genotyping for selecting patients with mCRC who are likely to respond to this treatment. However, the first phase 3 trial that has enrolled patients with KRAS mutation testing does not recommend this genetic testing. This letter describes the limitations of this meta-analysis and evaluates whether EGFR inhibitors should be administrated in mCRC patients based on KRAS mutational status.

(Citation: Gastric & Breast Cancer 2012; 11(1): 29-31)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 30 December 2011